SMS Terms & Conditions
How Does the Program Work?
Individuals can enroll in the SMS Program (the “Program”) via an online registration form. Individuals can select the option to receive SMS text messages. All individuals enrolled in the program will receive an enrollment confirmation text message. Message and data rates may apply. Message frequency will vary. Idorsia Pharmaceuticals (“Idorsia”) reserves the right to alter the frequency of messages sent at any time, so as to increase or decrease the total number of sent messages. Idorsia also reserves the right to change the short code or phone number from which messages are sent and we will notify you when we do so.
Your Consent to These Terms and Conditions:
By replying with a “YES” text message to confirm your participation in the SMS Program, you are consenting to the Terms and Conditions set forth below, with respect to receiving autodialed text messages sent from or on behalf of Idorsia. You agree that your response text is your electronic signature and provides electronic written consent. Consent is not a condition of purchase or use of any Idorsia product or service. Idorsia reserves the right to rescind, revoke or amend the Program without notice to you.
Use and Disclosure of Your Personal Information:
Data obtained from you in connection with the Program may include your phone number and related carrier information. This information may be used to administer the Program, including Program updates and alerts sent directly to your mobile device. Please see our Privacy Policy for more general information on how we may collect, use and disclose personal information about you.
Text Messages Sent to You:
The Program is valid with most major US carriers, but not all cellular phone providers carry the necessary service to participate. Participating Carriers: AT&T, Verizon Wireless, T-Mobile/Sprint/Metro PCS, CellCom USA, C Spire Wireless, U.S. Cellular, Carolina West Wireless (CWW), Google Voice, ACS/Alaska, Advantage Cellular (DTC Wireless), Appalachian Wireless, Bluegrass Cellular, Cellular Network Partnership (PIONEER), Cellular One of East Central Illinois, Chat Mobility USA, Coral Wireless (Mobi PCS), Element Mobile (Flat Wireless), Epic Touch (Elkhart Telephone), GCI Communications Corp, Golden State Cellular, Illinois Valley Cellular (IV Cellular), iWireless (IOWA Wireless), Nex-Tech Wireless, MTA Communications, MTPCS (Cellular One Nation), Cross Telephone Company (MBO Wireless), Duet IP (Maximum Communications New Core Wireless), Inland Cellular Telephone Company, Immix (Keystone Wireless), Mosaic (Consolidated or CTC Telecom), Northwest Missouri Cellular Limited, Peoples Wireless, Panhandle Telecommunications Systems (PTCI), RINA, Revol Wireless USA, SI Wireless/Mobile Nation, SRT Wireless, Texas RSA 3 Ltd (Plateau Wireless), Thumb Cellular, United Wireless, Union Telephone Company (Union Wireless), Viaero Wireless, West Central Wireless (5 Star Wireless), Sagebrush Cellular (Nemont), Pine Cellular, Aio Wireless/Cricket, Southern Linc, Bandwidth, Copper Valley, Leaco, Cablevision, Buffalo Wireless, Chariton Valley Cellular, Pine Belt Wireless, Atlantic Tele-Network International (ATN). T-Mobile is not liable for delayed or undelivered messages. The service is offered on an “as-is” basis and may not be available in all areas at all times and may not continue to work in the event of product, software, coverage or other changes made by your wireless carrier. Carriers are not responsible for delayed or undelivered messages. Check your phone capabilities for specific text messaging instructions. There is no fee charged to you for receiving Program messages that is payable to Idorsia or anyone acting on its behalf; however, your carrier’s message and data rates may apply depending on your individual wireless pricing plan, in accordance with your wireless customer agreement. You are responsible for all applicable taxes. Consult your wireless service provider regarding its pricing plans.
Participant Opt-Out or Help:
You may opt-out from participating in the Program at any time.
INDICATION
TRYVIO (aprocitentan), in combination with other antihypertensive drugs, is indicated for the treatment of hypertension to lower blood pressure (BP) in patients who are not adequately controlled on other drugs. Lowering BP reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. There are no controlled trials demonstrating reduction of risk of these events with TRYVIO.
Important Safety Information
WARNING: EMBRYO-FETAL TOXICITY
- TRYVIO can cause major birth defects if used by pregnant patients.
- In patients who can become pregnant, obtain a negative pregnancy test prior to initiation of TRYVIO and counsel patients to take monthly pregnancy tests during treatment and one month after discontinuation of TRYVIO.
- To prevent pregnancy, patients who can become pregnant should use acceptable methods of contraception before the start of, during, and for one month after stopping treatment.
- Because of the risk of birth defects, TRYVIO is only available through a restricted program called the TRYVIO Risk Evaluation and Mitigation Strategy (REMS).
CONTRAINDICATIONS
TRYVIO is contraindicated:
- in pregnancy. TRYVIO can cause fetal harm when administered during pregnancy.
- in patients who are hypersensitive to aprocitentan or any of its excipients.
WARNINGS AND PRECAUTIONS
Embryo-Fetal Toxicity and TRYVIO REMS
Based on data from animal reproduction studies with endothelin receptor antagonists (ERAs), TRYVIO can cause fetal harm when administered during pregnancy and is contraindicated for use in patients who are pregnant. Exclude pregnancy and ensure use of acceptable contraceptive methods prior to initiation of treatment with TRYVIO. If pregnancy is detected, discontinue TRYVIO.
TRYVIO is available only through a restricted program under a REMS called the TRYVIO REMS because of the risk of embryo-fetal toxicity. Important requirements of the TRYVIO REMS include:
- Prescribers must be certified with the TRYVIO REMS by enrolling in and completing training.
- Pharmacies that dispense TRYVIO REMS must be certified with the TRYVIO REMS.
Further information is available at www.TRYVIOREMS.com or 1-866-429-8964.
Hepatotoxicity
Elevations of aminotransferases and hepatotoxicity are known effects of ERAs, including TRYVIO. Elevations in alanine transaminase (ALT) or aspartate aminotransferase (AST) of greater than 5-fold upper limit of normal (ULN) were observed rarely in patients treated with aprocitentan in the clinical trial, including cases with positive rechallenge. To reduce the risk of potential serious hepatotoxicity, measure serum aminotransferase levels and total bilirubin prior to initiation of treatment and repeat during treatment periodically and as clinically indicated.
Do not initiate TRYVIO in patients with elevated aminotransferases (>3×ULN) or moderate to severe hepatic impairment. Advise patients with symptoms suggesting hepatotoxicity (nausea, vomiting, right upper quadrant pain, fatigue, anorexia, scleral icterus, jaundice, dark urine, fever, or itching) to immediately stop treatment with TRYVIO and seek medical attention.
If sustained, unexplained, clinically relevant aminotransferase elevations occur, or if elevations are accompanied by an increase in bilirubin >2×ULN, or if clinical symptoms of hepatotoxicity occur, discontinue TRYVIO.
Fluid Retention
Fluid retention and peripheral edema are known effects of ERAs, including TRYVIO. Edema/fluid retention was reported in 9% of TRYVIO-treated patients compared with 18% of patients receiving aprocitentan 25 mg (twice the recommended dose) and 2% on placebo in the clinical trial, requiring additional diuretic use in some patients. Older age and chronic kidney disease are risk factors for edema/fluid retention with TRYVIO. TRYVIO has not been studied in patients with heart failure New York Heart Association stage III-IV, unstable cardiac function, or with NTproBNP ≥500 pg/mL. TRYVIO is not recommended in these patients.
Monitor for signs and symptoms of fluid retention, weight gain, and worsening heart failure. If clinically significant fluid retention develops, treat appropriately, and consider discontinuation of TRYVIO.
Hemoglobin Decrease
Decreases in hemoglobin concentration and hematocrit have occurred following administration of other ERAs and were observed in the clinical trial with TRYVIO. Hemoglobin decreases usually presented early, stabilized thereafter, and were reversible after discontinuation. A decrease in hemoglobin of >2 g/dL from baseline was observed in 7% of patients compared to 1% of placebo patients. A decrease to below 10.0 g/dL was observed in 3% of TRYVIO-treated patients compared to 0 patients taking placebo. Initiation of TRYVIO is not recommended in patients with severe anemia. Measure hemoglobin prior to initiation of treatment and periodically during treatment as clinically indicated.
Decreased Sperm Counts
TRYVIO, like other ERAs, may have an adverse effect on spermatogenesis. Counsel men about potential effects on fertility.
MOST COMMON ADVERSE REACTIONS
The most common adverse reactions (more frequent than placebo and ≥2% in TRYVIO-treated patients) are edema/fluid retention and anemia.
USE IN SPECIFIC POPULATIONS
Lactation
Renal Impairment
TRYVIO is not recommended in patients with kidney failure (eGFR<15 mL/min) or on dialysis. Patients with renal impairment are at increased risk of edema/fluid retention.
Hepatic Impairment
TRYVIO is not recommended in patients with moderate and severe hepatic impairment (Child-Pugh class B and C) because these patients may be at increased risk for poor outcomes from hepatotoxicity.
